{
  "id": "512d0e635274a5fb07000005",
  "type": "factoid",
  "question": "Which is the most widely used anti-TNF drug?",
  "ideal_answer": "Etanercept is the most widely used anti-TNF drug.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21881980",
    "http://www.ncbi.nlm.nih.gov/pubmed/18420660",
    "http://www.ncbi.nlm.nih.gov/pubmed/22379032",
    "http://www.ncbi.nlm.nih.gov/pubmed/19854715",
    "http://www.ncbi.nlm.nih.gov/pubmed/21177290"
  ],
  "snippets": [
    {
      "text": "higher rates are observed with anti-TNF Abs (e.g., infliximab) as compared with TNF receptor fusion protein (etanercept).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22379032",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Two of them received etanercept and the remainder adalimumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21881980",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "45 cases were collected of non-TB OIs in 43 patients receiving infliximab (n=29), adalimumab (n=10) or etanercept (n=4)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21177290",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000894",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023201",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044966",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053199",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016756"
  ],
  "exact_answer": "Etanercept"
}